Back

Nanobiotix announces complete Phase 1 results for JNJ-1900 (NBTXR3)

Verifying
  • Nanobiotix announced complete Phase 1 results for JNJ-1900, also known as NBTXR3.
  • JNJ-1900 (NBTXR3) was evaluated in a full cohort of patients.
  • The announcement concerns inoperable, recurrent non-small cell lung cancer.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.